KMDA Kamada

Kamada Provides Update on 2021 GLASSIA® Supply to Takeda

Kamada Provides Update on 2021 GLASSIA® Supply to Takeda
EN
07/10/2020

Underlying

KMDAKamada

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kamada

 PRESS RELEASE
Free
KMDA KAMADA

Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenue...

Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance 2026 Guidance Represents Year-Over-Year Increase of 13% in Revenues and 23% in Adjusted EBITDA Based on Mid-Point of 2025 Annual Guidance2026 Annual Guidance is Based Solely on Continued Organic GrowthCompany Continues to Focus on Securing New Business Development and M&A Transactions to Accelerate Long-Term Profitable Growth Kamada Affirms 2025 Guidance of $178 Million - $182 Million in Revenues and $40 Millio...

January 7, 2026 1 EN
 PRESS RELEASE
Free
KMDA KAMADA

Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender

Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender Company Awarded Extension to Existing Supply Tender Relating to its Portfolio of Four Specialty Plasma-Derived ProductsSupply Extension Secures Ongoing Sales of Approximately $5.0-$7.0 Million Per Year for the Period Between Q2-26 and Q1-28Kamada Reiterates its 2025 Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 MillionKamada Projects Double-Digit Growth in Revenues and Profitability in 2026; Detailed Guidance to be Provided in January 2026 REHOVOT, Israel, and HOBOKEN, N....

December 18, 2025 1 EN
 PRESS RELEASE
Free
KMDA KAMADA

Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical T...

Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026 Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint Kamada Continues to Supply GLASSIA®, its AAT-IV Treatment, Marketed Internationally Including in the U.S. and Canada Through a License Agreement with TAKEDAKamada Reiterates its 2025 Full-Year Revenue Guidance of $178 Million-$182 Million and Adj...

December 8, 2025 1 EN
 PRESS RELEASE
Free
KMDA KAMADA

Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Resu...

Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth Third Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up 35% Year-over-Year Positive Outlook for Remainder of 2025 Based on the Company's Diverse Product Portfolio Supports Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million Generated $17.9 Million of Cash f...

November 10, 2025 1 EN
 PRESS RELEASE
Free
KMDA KAMADA

Kamada Announces First Patient Enrolled into an Investigator-Initiated...

Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation Post Marketing Study to Evaluate the Role of CYTOGAM in the Reduction of Risk of Late CMV Disease Following the Conclusion of Standardly Prescribed Antiviral Treatment in High-Risk Kidney Transplant Recipients REHOVOT, Israel, and HOBOKEN, N.J. , Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and...

November 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch